Related Experiment Video
Updated: Mar 25, 2026
07:54
Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
20.9K
The Relationship between Metformin and Obstructive Sleep Apnea.
Deborah Lin1, Lisa Rein2, Sergey Tarima2
1Clinical and Translational Science Institute, Medical College of Wisconsin (MCW), USA.
Journal of Sleep Medicine and Disorders
|February 23, 2016
Summary
Metformin use in type 2 diabetes patients was not significantly linked to obstructive sleep apnea. However, lower Hemoglobin A1c levels were associated with reduced obstructive sleep apnea prevalence.
Area of Science:
- Endocrinology
- Sleep Medicine
- Pharmacology
Background:
- Obstructive sleep apnea (OSA) is a common comorbidity in patients with type 2 diabetes (T2D).
- The potential impact of metformin, a first-line T2D medication, on OSA prevalence remains unclear.
Purpose of the Study:
- To investigate the association between metformin use and the prevalence of obstructive sleep apnea (OSA) in adult patients with type 2 diabetes (T2D).
Main Methods:
- Retrospective analysis of a secondary database involving 9,853 T2D patients with one year of follow-up.
- Metformin use was the primary variable; OSA status was the primary outcome.
- Key covariates included age, gender, race, hypertension, congestive heart failure, HbA1c, and BMI. A p-value <0.01 was considered significant.
Main Results:
- Metformin usage showed no significant association with OSA prevalence (OR: 1.17, CI: 1.00-1.36, p=0.049), though it trended towards an association with having OSA.
- Lower Hemoglobin A1c (HbA1c) levels were significantly associated with a lower prevalence of OSA (p <0.001).
- Other analyzed variables followed previously established associations.
Conclusions:
- Metformin therapy might enhance sleep quality, but not necessarily by reducing the risk of developing obstructive sleep apnea.
- Further research is warranted to establish a causal relationship regarding metformin and OSA prevalence.
More Related Videos
Related Concept Videos
01:21Sleep Apnea
753
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
753
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
919
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
919
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
368
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
368
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
809
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
809
01:13Insufficient Sleep and Sleep Deprivation
1.3K
Insufficient sleep refers to not getting the recommended amount of sleep for optimal functioning, even if it's just slightly less than needed. Sleep insufficiency may occur due to lifestyle choices, such as staying up late for social events or work, resulting in routinely getting less sleep than required. For example, consistently sleeping 6 hours when the body needs 7-9 hours can lead to cumulative effects on health and well-being.
Sleep deprivation is a more severe form of sleep loss...
Sleep deprivation is a more severe form of sleep loss...
1.3K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
845
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
845